Innoviva, Inc.
HealthcareNASDAQ:INVA · NASDAQ Global Select
+$0.30 today
Vol 0.56M · Avg 0.77M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.1%
avg 39.8%
ROIC
8.6%
avg 23.7%
ROA
16.6%
avg 22.1%
Analysis
ROE is currently the strongest return metric at 23.1% versus its period average of 39.8%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pavel Raifeld | Chief Executive Officer & Director | $1.00M | — | 42 | $285,929.00 | 0.39% |
Stephen Basso | Chief Financial Officer | $716,841.00 | — | 60 | $88,571.00 | 0.12% |
Marianne Zhen | Chief Accounting Officer & Secretary | $691,271.00 | — | 57 | $57,516.00 | 0.08% |
Patricia Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. | — | — | 59 | — | — |
David Altarac | Chief Medical Officer of IST | — | — | 64 | $0.00 | <0.01% |
Marcie Cain | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +112.6% | +17.9% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | +19.5% (15yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +112.6% over three years. Forward estimates point to EBIT at +19.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
Who manages INVA?
Innoviva, Inc. (INVA) lists 6 active executives. The top listed executive is Marianne Zhen, Chief Accounting Officer & Secretary.
Are INVA insiders buying or selling?
Recent insider activity shows net selling of $280.79M.
Explore More
Continue the stock analysis
Jump to another research area for this company.